SOURCE: Ablynx

October 23, 2009 12:24 ET


GHENT, BELGIUM--(Marketwire - October 23, 2009) -

GHENT, Belgium, 23 October 2009 - Ablynx [Euronext Brussels: ABLX] is pleased to announce it has been awarded 'Most Successful Early Phase Trial' at the 2009 Good Clinical Practice Journal's (GCPj) Clinical Research Excellence Awards in London. The GCPj's Awards recognise excellence in clinical research and development.

Commenting on the award, Chief Medical Officer Josi Holz said: "It is a great honour to receive this prestigious award. We are pleased that our lead programme, a novel anti-thrombotic, ALX-0081 entered a Phase II study in patients undergoing percutaneous coronary intervention (PCI) last month. The award recognises our innovative Phase I clinical trial design and the acceleration of this programme through the use of biomarkers and PK/PD modelling to establish biological effective dosing in patients. We have achieved the rapid progress with ALX-0081 thanks to a dedicated Ablynx team and our collaborators at the OLVZ in Aalst and PRA International."


About ALX-0681 and ALX-0081

ALX-0681 and ALX-0081 are novel "first-in-class" therapeutic Nanobodies® targeting von Willebrand factor ("vWF"), a protein found in the blood that acts at a very early stage in the coagulation cascade, namely platelet adhesion, in contrast to currently available anti-platelet drugs which act only in the late stage of platelet aggregation. ALX-0081 is administered intravenously while ALX-0681 is administered subcutaneously. ALX-0081 is a bivalent Nanobody® with a molecular weight of 28,000 daltons, designed to selectively prevent unwanted thrombus formation in vessels under high shear conditions without interfering with desirable haemostasis and, as such, to minimize bleeding complications.

About Ablynx [Euronext Brussels: ABLX] -

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 220 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007.

For more information, please contact:

College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, Dr John McIntyre
t:   +44 (0)20 7866 7857

Dr. Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68

Eva-Lotta Allan
Chief Business Officer
t:   +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.

Contact Information